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Abstract
Purpose The purpose of this study is to examine the
adequacy of treatment for constipation, nausea, depression
and poor sleep and the factors associated with inadequate
symptom control in cancer patients receiving opioids.
Methods Patients receiving strong opioids for cancer pain
were recruited from 17 centres in 11 European countries.
By using the European Organization for Research and
Treatment of Cancer Core Quality of Life Questionnaire
C30, 1,938 patients reported their symptoms at four-point
scales. Health care providers assessed symptoms at
corresponding four-point scales and registered use of
medications, demographic and disease-related variables.
Symptomatic treatment was scored as 1 if not administered
during the past 24 h and as 2 if administered. Adequacy of
treatment was evaluated by subtracting the patients’
symptom score from the treatment score. Negative scores,
caused by either no treatment or ineffective treatment of a
symptom, were interpreted as inadequate treatment.
Results Approximately 60% of patients with constipation,
depression or poor sleep and 45% of nauseated patients
were inadequately treated. Numbers of inadequately treated
patients varied between countries. In general, underestima-
tion of symptom intensity by health care providers (p<
0.001), low performance status (p<0.05) and recent
initiation of opioids (p<0.05) increased the risk of
inadequate treatment. The subset of demographic- and
disease-related factors associated with inadequate treatment
varied between the symptoms investigated.
Conclusions Inadequate treatment, either no treatment or
ineffective treatment, was frequent in cancer patients. There
were subgroups of patients at particular risk for inadequate
treatment, which might need additional attention from
health care providers for achievement of adequate symptom
control.
Keywords Constipation.Nausea.Depression.Sleep.
Opioid.Palliative care
Introduction
Constipation, nausea, depression and poor sleep are
frequent symptoms among patients with advanced cancer
[1, 2]. Several guidelines, mostly based on aggregated
clinical experience and expert recommendations, describe
how to treat symptoms in cancer patients [3–7]. Still,
symptoms like constipation, nausea, depression and poor
sleep are often inadequately treated [2, 7–10]. There are
inter-individual variations in both symptom susceptibility
and treatment response among cancer patients, but little is
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DOI 10.1007/s00520-010-1051-2known about which patients are at risk for inadequate
treatment.
Constipation affects at least 30–50% of cancer patients
[4, 8]. Guidelines emphasize the importance of regularly
prescribed laxatives for patients treated with opioids [3, 4],
but up to 90% are inadequately treated [1, 8]. Opioids
induce nausea in nearly 40% of patients [3]. The recom-
mended treatment is antiemetic drugs directed to the
underlying pathophysiological mechanism, although this
strategy often fails [3, 5, 9, 11]. Depression is found in
about half of advanced cancer patients [12]. Evidence
supports treating cancer-associated depression with psycho-
therapy, tricyclic antidepressants or selective serotonin
reuptake inhibitors [6]. Still, only a minority of depressed
patients with advanced cancer are treated with antidepres-
sants [6, 10]. If asked, most cancer patients report poor
sleep [13]. Removal of underlying physical and psycho-
logical factors as well as a hypnotic agent is usually needed
to treat poor sleep [7, 13]. However, poor sleep is often
neither recognized nor treated among patients with cancer
[7].
The inter-individual variations in symptom susceptibility
and treatment response may be related to demographic- and
disease-related factors, to differences in definition, assess-
ment and treatment of symptoms [14]. To improve
symptom control in cancer patients, current practice and
adequacy of treatment needs to be assessed [15]. Inade-
quately treated patients should be identified and character-
ized. To date, there is no agreement on how to evaluate
inadequate treatment of constipation, nausea, depression
and poor sleep. Three studies have identified inadequate
treatment of symptoms in cancer patients [8, 9, 16]. For
pain, variants of the pain management index (PMI) have
been used for assessment of the relationship between
symptom intensity and adequacy of treatment [17–19]. In
the present study, the relationship between symptom
intensity and treatment was utilized to (1) examine the
adequacy of treatment for constipation, nausea, depression
and poor sleep, and to (2) examine whether demographic-
and disease-related factors are associated with inadequate
control of these symptoms.
Methods
Patients
Between February 2004 and April 2008, 2,294 cancer
patients from 17 centres in 11 European countries were
included in the cross-sectional European Pharmacogenetic
Opioid Study. Patients were18 years old or more, had a
verified malignant disease and were treated for at least
3 days with a scheduled opioid corresponding to the World
Health Organization’s (WHO) analgesic ladder step III for
cancer pain. Patients were excluded if not proficient in the
language of the study centre. Three hundred and fifty-six
patients did not give self-report of symptoms because they
were too ill (48%), did not want to complete the
questionnaire (40%) or for unknown reasons (12%).
Accordingly, 1,938 patients completed the symptom assess-
ments and were included in the analyses.
Ethics
The study was performed in accordance with the Declara-
tion of Helsinki. Each country’s or study centre’s ethical
committee approved the study. Each patient gave written
informed consent before inclusion.
Data collection
Health care providers (physician or nurse) registered patient
characteristics: age, weight, height, time since diagnosis
(months), time since start of opioids (months), gender,
status of opioid treatment (recently initiated and still under
titration or stable dosing), department (hospitalized or
outpatient), previous abuse of alcohol and/or drugs (yes or
no), metastases and cancer diagnosis. The mini mental state
(MMS) examination was performed to identify cognitive
failure (total score of 23 or less) [20, 21]. Functional status
was assessed by the Karnofsky performance status [22].
The use of all medications during the past 24 h (including
opioids and chemotherapy) were obtained from the
patients’ medical records. Providers also assessed constipa-
tion, nausea, depression and poor sleep during the past 24 h
on four-point verbal rating scales with the descriptors none
(1), mild (2), moderate (3) and severe (4). By using the
European Organization for Research and Treatment of
Cancer Core Quality of Life Questionnaire C30 (EORTC-
QLQ-C30) version 3.0, the same symptoms were reported
by patients on corresponding four-point scales for the past
week on average [23].
Data analysis
Administration of medications is presented as absolute
numbers and percentages of untreated and treated patients.
Mann–Whitney U tests were performed to investigate
whether the numbers of untreated and treated patients
varied in relation to symptom intensity.
To examine the adequacy of symptomatic treatment, an
approach utilizing the relationship between symptom
intensity and treatment was used. This strategy was based
upon three previous studies describing adequacy of symp-
tomatic treatment in cancer patients [8, 9, 16] and a
validated method for assessing the adequacy of cancer pain
2006 Support Care Cancer (2011) 19:2005–2014treatment, the PMI [17–19]. Treatment was scored as 1 if
no drug was administered and as 2 if a drug was
administered for symptom control during the past 24 h
(Fig. 1). The patients’ symptom score was subtracted from
the treatment score. By calculating this score, patients were
separated into two groups: the adequately and the inade-
quately treated (Fig. 1). As for the PMI, negative scores
were interpreted as inadequate treatment [18]. Based on
previous studies, inadequate treatment was interpreted as
including both patients not receiving any treatment for their
reported symptoms and patients receiving treatment but still
reporting moderate or severe symptoms (Fig. 1)[ 8, 9].
For each symptom, the subgroups of adequately (posi-
tive scores or zero) and inadequately treated patients
(negative scores) were compared with respect to
demographic- and disease-related factors. Mann–Whitney
U tests were performed for continuous data, and Fisher’s
exact tests were performed for categorical data (2×2
tables).
Multiple logistic regression analyses were used to
examine the association between inadequate treatment and
demographic-, as well as disease-related factors. The
dependent variable was inadequate versus adequate treat-
ment. Four separate multiple logistic regressions were
performed, one for each of the symptoms investigated.
Based on clinical experience and the existing literature on
prevalence of symptoms and adequacy of treatment, the
factors considered for inclusion as independent variables
were age [16], discrepancy in symptom scores between
health care providers and patients (provider score minus
patient score) [19, 24], body mass index (BMI) [25],
number of medications administered the past 24 h (exclud-
ing opioids) [25, 26], gender [18], Karnofsky performance
status [19], total MMS score [4], time since diagnosis [12,
27], affiliation to department, presence of pain during the
past week [6, 27], status of opioid treatment [3, 28],
previous or ongoing abuse of alcohol and/or drugs [5, 29],
use of chemotherapy during the past 24 h [30], presence of
metastases [19] and cancer diagnosis. Univariate logistic
regression analyses were used to screen for an association
between these factors and the dependent variable. A factor
was considered as a candidate for inclusion in the multiple
logistic regression analysis if it was marginally associated
with the dependent (p≤0.25) [18]. Independent factors
considered as candidates after univariate regressions (p≤
0.25) were entered into the backward multiple logistic
regression analyses with F>0.05 as criterion for removal.
All multiple logistic regression models were stratified by
country.
The statistical software SPSS for Windows v. 16.0 was
used for all statistical analyses except the stratified multiple
logistic regressions, which were performed by using the
statistical software STATA version 11.0.
Results
Patients
The mean age was 62±12 years, mean Karnofsky perfor-
mance status was 62±16, mean MMS score was 27±3,
mean time since diagnosis was 33±47 months and mean
time since initiation of opioid treatment was 5±11 months.
Genders were equally represented (48% female). Most
patients received stable opioid dosing (81%) and were
hospitalized (78%). The percentages of patients reporting
moderate or severe symptoms were higher among the
hospitalized than among outpatients (data not shown).
Percentages of patients reporting the symptom intensity as
moderate or severe were for constipation 45%, nausea 27%,
depression 31% and poor sleep 32% (Table 1). Figure 2
shows the intensities of symptoms as reported by patients
and health care providers. The distribution of patients with
respect to country is given in Table 2.
Treatment of symptoms
Although all patients in this study received strong opioids,
almost half of them were not given any laxative during the
past 24 h (Table 1). For patients reporting moderate or
severe constipation, 41% and 27% were not given any
laxative treatment. Bulk laxatives were the most commonly
administered laxatives (Table 1). Antiemetic drugs were
given to approximately 40% of all patients (Table 1).
Thirty-one percent of the patients reporting severe nausea
were not treated. Approximately 20% of patients were
prescribed an antidepressant (Table 1). However, 74% of
the patients reporting quite a bit depression and 72% of
those reporting very much depression were not given any
medications for symptom relief. Close to 80% of patients
Symptom intensity  
score 
Treatment score 
Not at all (1)  A little (2)  Quite a bit (3)  Very much (4) 
No drug for relief (1)  0  -1  -2  -3 
Drug for relief (2)  +1  0  -1  -2 
Fig. 1 The relationship between symptom intensity and treatment calculated by subtracting patients’ symptom score from treatment score. Green
colour symbolizes adequate treatment; blue colour symbolizes inadequate treatment
Support Care Cancer (2011) 19:2005–2014 2007reporting severe sleeping difficulties were not treated with
hypnotics (Table 1). The most common type of hypnotics
was benzodiazepine-like drugs. Treatment was more fre-
quently administered for higher intensities of constipation,
nausea and depression (p<0.001), whereas no such rela-
tionship was found for poor sleep (p=0.077; Table 1).
Almost 60% of patients were inadequately treated for
constipation, depression and poor sleep (defined as treatment
score minussymptomscore<0; Table 2). Of patients reporting
nausea, 44% were classified as inadequately treated.
Characteristics of the inadequately treated and factors
associated with inadequate symptom control
The characteristics of inadequately treated patients are
shown in Table 2. For all symptoms investigated, patients
inadequately treated were characterized by provider under-
estimation of symptom intensity (p<0.001), lower Karnof-
sky performance status (p<0.05), hospitalization (p<0.05),
more pain (p<0.05) and recent initiation of opioid treatment
(p<0.05; Table 2). Also, the number of patients inade-
quately treated varied between countries with for instance
fewer patients in Denmark and Iceland, and more patients
in Lithuania and Germany being evaluated as inadequately
treated (Table 2). Some of the demographic- and disease-
related factors differed significantly between the adequately
and the inadequately treated (Table 2) but were not retained
as factors associated with inadequate symptom control in
multiple logistic regression (Table 3).
The factors that were marginally associated (p≤0.25)
with the dependent in univariate analyses (data not shown)
were included in the multiple logistic regression analyses.
Six factors were retained as associated with inadequate
treatment for constipation after multiple logistic regressions
(Table 3). In addition to the underestimation of intensity by
providers (p<0.001), also lower performance status (p=
0.014), recent initiation of opioids (p=0.029) and one or
more metastases (p=0.043) increased the risk of inadequate
treatment. Patients reporting abuse of alcohol and/or drugs
(p=0.002) and patients with gastrointestinal cancer (p=
0.035) had lower risk of being inadequately treated for
constipation (Table 3).
The risk of being inadequately treated for nausea was
increased in younger patients (p=0.023), if health care
provider underestimated nausea intensity (p<0.001), if
opioid titration was still ongoing (p=0.018) and if the
patient had cancer of the female reproductive organs (p<
0.015; Table 3). Patients reporting abuse of alcohol and/or
2008 Support Care Cancer (2011) 19:2005–2014
Table 1 Symptomatic treatment administered
Symptom Treatment during the past
24 h
Total
(N=2,294)
a
Symptom intensity among patients self-reporting
(N=1,938)
Mann–Whitney
U test
Not at all A little Quite a bit Very much
N (%) N (%) N (%) N (%) N (%) α
Constipation No laxative 1,099 (48.1) 391 (67.1)
b 251 (52.6)
c 194 (40.8)
c 106 (27.0)
c <0.001
Laxative 1,185 (51.9) 192 (32.9)
b 226 (47.4)
b 281 (59.2)
c 286 (73.0)
c
Bulk laxative 579 (49.0) 101 (52.6) 122 (54.2) 117 (41.6) 117 (41.1) 0.001
Stimulant laxative 261 (22.1) 44 (22.9) 53 (23.6) 75 (26.7) 46 (16.1) 0.080
Other laxative 342 (28.9) 47 (24.5) 50 (22.2) 89 (31.7) 122 (42.8) <0.001
Nausea No antiemetic 1,404 (61.5) 641 (73.4)
b 325 (61.2)
c 147 (43.0)
c 58 (31.2)
c <0.001
Antiemetic 880 (38.5) 232 (26.2)
b 206 (38.8)
b 195 (57.0)
c 128 (68.8)
c
Depression No antidepressant 1,833 (80.3) 544 (85.0)
b 546 (79.7)
c 294 (73.7)
c 138 (71.9)
c <0.001
Antidepressant 451 (19.7) 96 (15.0)
b 139 (20.3)
b 105 (26.3)
c 54 (28.1)
c
Poor sleep No hypnotic 1,887 (82.6) 610 (82.8)
b 482 (84.0)
c 323 (78.8)
c 166 (79.4)
c 0.077
Hypnotic 397 (17.4) 127 (17.2)
b 92 (16.0)
b 87 (21.1)
c 43 (20.6)
c
Barbiturates 2 (0.5) 1 (0.8) 0 1 (1.1) 0 0.855
Benzodiazepine-derivates 44 (10.9) 12 (9.4) 8 (8.6) 10 (11.1) 4 (9.3) 0.715
Benzodiazepine-like 347 (86.3) 113 (88.3) 82 (88.2) 76 (84.4) 39 (90.7) 0.741
Other hypnotics 9 (2.2) 2 (1.6) 3 (3.2) 3 (3.3) 0 0.921
Numbers and percentages of untreated and treated patients within each of the symptom intensity groups
Mann–Whitney U tests were performed to investigate whether the numbers of untreated and treated patients varied in relation to symptom
intensity
aThere were missing data for ten patients on treatment yes/no, for 1,112 patients on laxative category and for 1,892 patients on hypnotic drug category
bAdequate treatment
cInadequate treatmentdrugs had lower risk of being inadequately treated for
nausea (p=0.042; Table 3).
More patients were inadequately treated among those
who rated their depression as more severe than the health
care providers did (p<0.001), had lower BMI (p=0.043),
lower performance status (p<0.001), lower total MMS
score (p<0.001), were reporting pain during the past week
(p=0.005), were still undergoing opioid titration (p<0.001)
or had other cancer (e.g. sarcoma, skin or brain tumour; p=
0.034; Table 3).
Patients were more likely to be inadequately treated for
poor sleep if they were younger (p<0.001), if health care
providers rated the symptom as less severe than the patients
(p<0.001), if the patient received fewer medications (p<
0.001), if male (p=0.034), if the performance status was
lower (p<0.001), if the patient was hospitalized (p=0.008)
or had cancer classified as other (e.g. sarcoma, skin or brain
tumour; p=0.004; Table 3).
Discussion
The main finding of this study was that constipation, nausea,
depression and poor sleep were inadequately controlled in a
large number of European cancer patients receiving opioids.
Inadequate treatment of all symptoms was associated with
symptom underestimation by health care providers. Among
the factors associated with inadequate treatment of symptoms
were also lower age, lower Karnofsky performance status,
recent initiation of opioids, reporting of no abuse and certain
cancerdiagnoses.Despite advancesofsymptomatic treatment
in cancer care, major challenges remain in developing and
implementing effective guidelines for achievement of ade-
quate symptom control.
Interpretation of inadequate treatment
In the present study, the relationship between symptom
level and treatment level was utilized to define inadequate
treatment. As there was no previous clear-cut definitions,
we based our definitions on the existing literature which
was two studies on nausea [9, 16], one study on
constipation [8] and several studies on adequacy of pain
management [17]. Still, at least three aspects of the
subtraction approach (treatment level minus symptom level)
need to be addressed. First, symptoms may differ in respect
to whether lack of treatment for patients reporting ‘a little’
symptoms should be interpreted as inadequate treatment.
Whereas opioid-treated patients reporting a little constipa-
tion clearly should have laxatives [3, 4], physicians are
probably more reluctant to prescribe hypnotics for patients
reporting a little sleeping difficulties. To investigate how
defining also patients reporting ‘a little’ symptoms as
adequately treated would influence the findings, logistic
regressions were performed, showing that most factors
persisted (constipation five of six, nausea two of four,
depression four of five and poor sleep three of five).
Second, inadequate treatment included both patients not
treated and patients reporting symptoms despite treatment
(e.g. wrong drug, insufficient dose and true treatment-
resistant symptoms). It might be argued that the term
inadequate treatment is inappropriate for treatment-resistant
symptoms, but previous studies have shown that many
patients within this group actually receive suboptimal doses
or the wrong drug [8, 9, 11]. Third, there could be specific
clinical reasons for not administering treatment, such as
interactions, allergy or patient barriers. Therefore, future
studies should segregate such specific reasons from lack of
good clinical practice.
patient observer patient observer observer patient observer patient
0 %
20 %
40 %
60 %
80 %
100 %
symptoms assessed
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severe moderate mild none
constipation nausea depression poor sleep
Fig. 2 Symptom prevalence
and intensity as rated by
patients and health care
providers (observer)
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Table 2 Characteristics of patients receiving adequate and inadequate treatment
Inadequate treatment of symptoms Constipation Nausea Depression Poor sleep
No Yes No Yes No Yes No Yes
Age 61.5 61.7 62.1 61.1 62.2 61.2 63.6 60.2***
Assessment discrepancy (provider–patient) 0.1 −0.7*** 0.0 −0.9*** 0.1 −0.7*** 0.2 −0.7***
Body mass index 23.8 23.7 23.8 23.6 24.1 23.5** 23.9 23.6
Number of medications, except opioids 6.9 6.6* 7.0 6.5** 6.8 6.7 6.9 6.6*
N
a % Inadequate % Inadequate % Inadequate % Inadequate
Gender Male 1,013 58 41** 59 59*
Female 925 58 47 60 55
Karnofsky performance
status
≤80 1,824 59* 45* 61*** 58**
> 8 0 1 1 1 4 83 23 94 4
Mini mental state, total
score
≤23 258 52* 37* 66* 55
>23 1,568 58 45 58 58
Time since diagnosis
(months)
≤3 404 57 44 62 60
>3 1,367 59 43 59 57
Department Hospitalized 1,518 59* 46** 63*** 59**
Outpatients 420 53 37 47 51
Pain intensity (the past
week)
No 124 48* 29*** 39*** 27***
Yes 1,804 59 45 61 59
Status of opioid treatment Initiation, titration 356 65** 53*** 67** 64**
Stable dosing 1,566 56 42 58 56
Abuse alcohol and/or drugs No 1,813 59* 45* 59 57
Yes 115 47 34 61 61
Chemotherapy the past 24 h No 1,643 57 44 60 56
Yes 295 62 43 58 61
Metastases None 332 50** 47 59 57
One or more 1,605 60 44 59 57
Cancer diagnosis
b Breast 269 63 46 57 51*
Female reproductive
organ
c
145 59 58*** 53 59
Gastrointestinal 444 50*** 41 59 57
Haematological 113 59 45 56 62
Head and neck 105 51 40 65 53
Lung 347 62 44 61 59
Other 169 63 48 65 68*
Prostate 230 60 44 53* 54
Unknown origin 51 54 37 57 54
Urological 139 63 41 66 57
Country Denmark 29 21*** 24* 21*** 41
Finland 30 67 32 50 47
Germany 274 57 54** 85*** 74***
Greece 5 60 40 25 40
Iceland 145 39*** 35* 32*** 30***
Italy 400 68*** 27*** 57 62*
Lithuania 54 78** 50 80** 78**
Norway 477 61 58*** 58 55
Sweden 119 46** 54* 76*** 43**
Switzerland 114 58 45 77*** 75***
UK 291 54 40 42*** 50*
Comparison of the patients interpreted as adequately treated (positive scores or zero after subtracting the symptom score from the treatment score)
and inadequately treated (negative scores). Continuous data are reported as mean and compared by Mann–Whitney U tests. Categorical data are
reported as percentages within each subcategory and compared by Fisher’s exact test
*p<0.05; **p<0.01; ***p<0.001
aN is the absolute number of patients in each group. The sum and numbers may vary for symptoms due to missing data
bSome patients had more than one cancer diagnosis; consequently, the sum of percentages is larger than 100
cFemale reproductive organ is short for cancer of the female reproductive organsSupport Care Cancer (2011) 19:2005–2014 2011
Table 3 Factors significantly associated with inadequate symptom control
Constipation Nausea Depression Poor sleep
Age
a OR
b 0.78 0.97
95% CI 0.62 to 0.97 0.96 to 0.98
p 0.023 <0.001
Assessment discrepancy (provider–patient score) OR
b 0.22 0.13 0.16 0.23
95% CI 0.18 to 0.26 0.10 to 0.17 0.12 to 0.20 0.19 to 0.27
p <0.001 <0.001 <0.001 <0.001
Body mass index OR
b 0.97
95% CI 0.95 to 1.00
p 0.043
Number of medications, excluding opioids OR
b 0.93
95% CI 0.90 to 0.96
p <0.001
Gender OR
b 0.74
0: male 95% CI 0.60 to 0.92
1: female p 0.006
Karnofsky performance status OR
b 0.59 0.39 0.48
0: ≤80 95% CI 0.38 to 0.90 0.26 to 0.58 0.31 to 0.75
1: >80 P 0.014 <0.001 0.001
Mini mental state, total score OR
b 0.65
0: ≤23 95% CI 0.47 to 0.91
1: >23 p 0.011
Department OR
b 0.70
0: hospital 95% CI 0.54 to 0.91
1: outpatient p 0.008
Pain (intensity past week) OR
b 1.96
0: none 95% CI 1.22 to 3.13
1: little, quite, very p 0.005
Status of opioid treatment OR
b 0.73 0.73 0.73
0: initiation, titration 95% CI 0.55 to 0.97 0.55 to 0.96 0.53 to 1.00
1: stable dosing p 0.029 0.025 0.047
Abuse alcohol and/or drug OR
b 0.51 0.62
0: no 95% CI 0.33 to 0.78 0.40 to 0.98
1: yes p 0.002 0.042
Metastases OR
b 1.31
0: none 95% CI 1.01 to 1.71
1: one or more p 0.043
Type Gastrointestinal Female reproductive organ
c Other Other
Cancer diagnosis OR
b 0.77 1.69 1.64 1.78
0: no 95% CI 0.61 to 0.98 1.11 to 2.57 1.04 to 2.59 1.20 to 2.64
1: yes p 0.035 0.015 0.034 0.004
The dependent variable was inadequate versus adequate treatment. Negative scores after subtraction of the patient’s symptom score from the
treatment score were recoded as one and represented inadequate treatment, whereas zero or positive scores were recoded as zero and represented
adequate treatment
OR odds ratio, CI confidence interval
aFor nausea, the age variable was dichotomized into patients ≤60 and >60 years [30]. For constipation, depression and poor sleep, the age variable was
continuous (years)
bAn odds ratio above 1 reflects more under-treatment
cFemale reproductive organ is short for cancer of the female reproductive organsCharacterization of treatment
Inadequate treatment of constipation, nausea, depression and
poor sleep was widespread in European cancer patients
(Table 1). In line with previous findings, constipation was
inadequately controlled in 60% of patients [1, 8]. A recent
study concluded that inadequate treatment of nausea in
advanced cancer is now infrequent, as prescription of
antiemetics has increased from 32% in 1986 to 68% in
2008 [9]. This conclusion is challenged by the present study,
showing that only 38% of patients were given an antiemetic
and that nearly half of nauseated patients were inadequately
treated. Of patients reporting moderate or severe depression,
70% did not receive an antidepressant. The number of
patients fulfilling the criteria of a depressive disorder was
unknown in the present study, but the high number of
untreated may reflect a lack of effective communication and
clearly established diagnostic and therapeutic procedures,
which are known barriers to prescription of antidepressants
[6]. Approximately 20% of patients received a hypnotic drug
in the present study, which was lower than the range (58–
85%) previously described as under-prescription [10, 13],
but in line with a more recent study among cancer patients
attending outpatient clinics where approximately 20%
received sleeping pills [27].
Inadequate symptom control: characteristics of patients
and factors contributing
The presence of inadequate treatment differed between
countries. Variations in use of symptomatic treatment across
Europeancountrieshavebeendocumentedpreviously[2]a n d
may reflect the lack of well-designed, randomized controlled
trials and multinational guidelines on symptomatic treatment.
In addition, the variability may reflect differences in opioid
availability [31], the range of different services providing
supportive care and the differences between patient popula-
tions admitted to these services [32] .T h eo b s e r v e dd i f f e r -
ences between countries are of interest and should be
explored further. However, with the above-mentioned
influences and because this study only included a selection
of centres in each country, we are cautious in our
interpretation of the observed country-related differences.
Underestimation of symptom intensity by providers was
consistently associated with inadequate treatment of all
symptoms investigated. Underestimation of pain is a barrier
topainmanagement[18, 19], and the present findings indicate
that underestimation may hamper adequate treatment of other
symptoms as well. This finding is of particular importance for
cancer patients not able to report their own symptoms.
The factors associated with inadequate treatment of
constipation were compatible with clinical experience.
Patients with lower Karnofsky performance status have
reduced physical activity, which makes constipation more
difficult to treat [4]. Constipation encountered during
opioid titration can be a dose-limiting adverse effect [3].
Patients that abuse alcohol often have diarrhoea, and
constipation may therefore be less problematic [29].
Patients with metastatic disease can be constipated for
reasons that need other treatment approaches than antie-
metic drugs (e.g. metastases compressing the spinal cord
and malignant bowel obstruction) [4]. In patients with
gastrointestinal cancer, the lower risk of inadequate
treatment is perhaps a result of an increased focus on
treatment of gastrointestinal symptoms.
Lower age and cancer of the female reproductive organs
were associated with inadequate control of nausea, which
may reflect that both younger patients and women are more
prone to nausea [30]. The association with opioid titration
possibly reflects that nausea can be difficult to treat in this
phase and that antiemetics may be retained because
tolerance to nausea often develops quite fast [3]. The
association with ‘no abuse’ could reflect that emesis may be
more easily controlled in patients abusing alcohol [5].
Regarding inadequate treatment of depression, the
association with other (rarer) cancer diagnoses was difficult
to explain. Still, most of the factors fitted with clinical
experience as depression is closely related to lower BMI
[25] and lower Karnofsky performance status [33], as it is
difficult to separate depression from declining cognitive
functions [21] and as pain and depression can be more
difficult to treat when they appear together [6].
The association between inadequate treatment of poor
sleep and lower age may reflect that physicians fear
dependency in the younger and therefore are more reluctant
to prescribe hypnotics [7] or that prescription of hypnotics
is more common in patients predisposed to sleep difficulties
(e.g. the elderly and women) [13]. Age and gender-related
differences in use of hypnotics were not present in a
previous study [26]. The association with number of other
medications may reflect that providers were aware that
hypnotics often contribute to polypharmacy [25, 26].
Inadequately treated poor sleep in patients with lower
performance status may reflect that bedridden, deteriorating
patients need other treatment than hypnotics [7]. The
association with hospitalization was not unexpected, as
the hospitalized are more ill, receive more concomitant
treatments and have disruptions of their habitual lifestyles
in general [7]. The association with other (rarer) cancer
diagnoses was difficult to explain.
Implications
The approach for evaluation of inadequate treatment
applied in this study could be used at a group level as a
quality indicator for treatment of symptoms in advanced
2012 Support Care Cancer (2011) 19:2005–2014cancer [15] and could increase comparability between
future studies. The present findings indicate that manage-
ment of symptoms other than pain may be subject to some
of the same barriers as pain treatment [1, 17, 18, 34]. Future
research addressing specific barriers towards symptomatic
treatment in cancer care would be of interest.
Limitations
Toour knowledge,this is the largest studyaddressingadequacy
of symptomatic treatment in European cancer patients. How-
ever, we recognize that the study have some limitations. First,
treatments administered were registered for the past 24 h,
whereas symptoms were reported for the past week. However,
that treatment was not initiated at the study day despite patient
reports of moderate or severe symptoms for 1 week strengthen
the evidence for a lack of adequate initiation of treatment.
Second, all details about the treatments (time since initiation,
type and dosage and administration route) were not collected.
For the analyses, we chose to use the presence or lack of
symptomatic treatment. It is difficult to evaluate the adequacy
of choice of specific medications and dosages because there is
no gold standard (recommendations) representing the correct
treatment. Third, data on numbers and characteristics of
patients not approached or declining to take part in the study
was not obtained. However, a large number of patients were
included, and their characteristics were as expected for a cancer
pain patient cohort. Finally, separate studies are needed to
addresstheaccuracy,validityandreliabilityofthedefinitionsof
inadequate treatment used in this study.
Conclusions
Inadequate treatment of symptoms, either no treatment or
ineffective treatment, was frequent among European cancer
patients.Patientsratingtheirsymptomsasmoreseverethanthe
providers, with lower Karnofsky performance status or
undergoing opioid titration were at particular risk for inade-
quate treatment. The subset of demographic- and disease-
related factors associated with inadequate treatment varied
between the symptoms investigated. The health care system
needs to implement guidelines for symptomatic treatment,
health care providers need to improve their symptom
assessment and patients characterized by the presence of
certain risk factors for inadequate treatment need special
attention to provide better symptom control in cancer care.
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